Login / Signup

Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study.

Stephen D SilbersteinMerle DiamondNada A HindiyehDavid M BiondiRoger CadyJoe HirmanBrent AllanSusan PedersonBarbara SchaefflerJeff Smith
Published in: The journal of headache and pain (2020)
ClinicalTrials.gov (Identifier: NCT02974153 ). Registered November 23, 2016.
Keyphrases
  • high dose
  • big data
  • machine learning
  • combination therapy
  • gestational age
  • drug induced
  • deep learning
  • smoking cessation